<PAGE>
------------------------------
OMB APPROVAL
[x] Check box if no longer ------------------------------
subject to Section 16. Form 4 or OMB Number 3235-0287
Form 5 obligations may continue. Expires: December 31, 2001
See Instruction 1(b).
------------------------------
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
______________________________________________________________________________
1. Name and Address of Reporting Person*
GLAXO WELLCOME INC.
______________________________________________________________________________
(Last) (First) (Middle)
7333 Mississauga Road North
______________________________________________________________________________
(Street)
Mississauga, Ontario L5N,6L4, Canada
______________________________________________________________________________
(City) (State) (Zip)
______________________________________________________________________________
2. Issuer Name and Ticker or Trading Symbol
CliniChem Development Inc. (CCHE)
______________________________________________________________________________
3. IRS Identification Number of Reporting Person, if an Entity (Voluntary)
N/A
______________________________________________________________________________
4. Statement for Month/Year
July 2000
______________________________________________________________________________
5. If Amendment, Date of Original (Month/Year)
N/A
==============================================================================
6. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
[_] Director [x] 10% Owner
[_] Officer (give title below) [_] Other (specify below)
______________________________________________________________________________
7. Individual or Joint/Group Filing (Check applicable line)
[_] Form filed by One Reporting Person
[x] Form filed by more than One Reporting Person
______________________________________________________________________________
Page 1 of 4
<PAGE>
<PAGE>
================================================================================
Table I -- Non-Derivative Securities Acquired, Disposed of,
or Beneficially Owned
================================================================================
<TABLE>
<CAPTION>
6.
4. 5. Owner-
Securities Acquired (A) or Amount of ship
3. Disposed of (D) Securities Form: 7.
Transaction (Instr. 3, 4 and 5) Beneficially Direct Nature of
2. Code ------------------------------- Owned at End (D) or Indirect
1. Transaction (Instr. 8) (A) of Month Indirect Beneficial
Title of Security Date ------------ Amount or Price (Instr. 3 (I) Ownership
(Instr. 3) (month/day/year) Code V (D) and 4) (Instr.4) (Instr. 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
------------------------------------------------------------------------------------------------------------------------------------
Class A Common Shares 07/28/2000 S 396,274 D $9.63 -0- D (See
(1) below)
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
</TABLE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
* If the Form is filed by more than one Reporting Person, see Instruction
4(b)(v).
(Over)
SEC 1474(3-99)
Page 2 of 4
<PAGE>
FORM 4 (continued)
Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
===============================================================================
<TABLE>
<CAPTION>
10.
9. Owner-
Number ship
of Form
2. Deriv- of
Conver- 5. 7. ative Deriv- 11.
sion Number of Title and Amount Secur- ative Nature
of Derivative 6. of Underlying 8. ities Secur- of
Exer- 4. Securities Date Securities Price Bene- ity: In-
cise 3. Trans- Acquired (A) Exercisable and (Instr. 3 and 4) of ficially Direct direct
Price Trans- action or Disposed Expiration Date ---------------- Deriv- Owned (D) or Bene-
1. of action Code of(D) (Month/Day/Year) Amount ative at End In- ficial
Title of Deriv- Date (Instr. (Instr. 3, ---------------- or Secur- of direct Owner-
Derivative ative (Month/ 8) 4 and 5) Date Expira- Number ity Month (I) ship
Security Secur- Day/ ------ ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr.
(Instr. 3) ity Year) Code V (A) (D) cisable Date Title Shares 5) 4) 4) 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
</TABLE>
Page 3 of 4
Explanation of Responses:
(1) At the time of disposition, these 396,274 shares were held of record
by the Reporting Person on behalf of its parent company,
Glaxo Wellcome International B.V.
Pursuant to Rule 16a-1(a)(4) promulgated under the Securities Exchange Act
of 1934, as amended, the Reporting Person herein states that this filing
shall not be deemed an admission that he or it is the beneficial owner of
any of the securities covered by this Statement.
** Intentional misstatements or omissions of facts
constitute Federal Criminal Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be
manually signed. If space is insufficient, see
Instruction 6 for procedure.
Potential persons who are to respond to the collection of
information contained in this form are not required to
respond unless the form displays a currently valid OMB
Number.
GLAXO WELLCOME INC. August 7, 2000
--------------------------------------------- ---------------
By: /s/ Patrick M. McGrade Date
--------------------------------------
Name: Patrick M. McGrade
Title: Assistant Corporate Secretary
** Signature of Reporting Person
Page 4 of 4
<PAGE>
<PAGE>
------------------------------
OMB APPROVAL
[x] Check box if no longer ------------------------------
subject to Section 16. Form 4 or OMB Number 3235-0287
Form 5 obligations may continue. Expires: December 31, 2001
See Instruction 1(b).
------------------------------
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
______________________________________________________________________________
1. Name and Address of Reporting Person*
GLAXO WELLCOME INTERNATIONAL B.V.
______________________________________________________________________________
(Last) (First) (Middle)
Huis ter Heideweg 62
______________________________________________________________________________
(Street)
2705 LZ, Zeist, The Netherlands
______________________________________________________________________________
(City) (State) (Zip)
______________________________________________________________________________
2. Issuer Name and Ticker or Trading Symbol
CliniChem Development Inc. (CCHE)
______________________________________________________________________________
3. IRS Identification Number of Reporting Person, if an Entity (Voluntary)
N/A
______________________________________________________________________________
4. Statement for Month/Year
July 2000
______________________________________________________________________________
5. If Amendment, Date of Original (Month/Year)
N/A
==============================================================================
6. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
[_] Director [x] 10% Owner
[_] Officer (give title below) [_] Other (specify below)
______________________________________________________________________________
7. Individual or Joint/Group Filing (Check applicable line)
[_] Form filed by One Reporting Person
[x] Form filed by more than One Reporting Person
______________________________________________________________________________
Page 1 of 4
<PAGE>
<PAGE>
================================================================================
Table I -- Non-Derivative Securities Acquired, Disposed of,
or Beneficially Owned
================================================================================
<TABLE>
<CAPTION>
6.
4. 5. Owner-
Securities Acquired (A) or Amount of ship
3. Disposed of (D) Securities Form: 7.
Transaction (Instr. 3, 4 and 5) Beneficially Direct Nature of
2. Code ------------------------------- Owned at End (D) or Indirect
1. Transaction (Instr. 8) (A) of Month Indirect Beneficial
Title of Security Date ------------ Amount or Price (Instr. 3 (I) Ownership
(Instr. 3) (month/day/year) Code V (D) and 4) (Instr.4) (Instr. 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
------------------------------------------------------------------------------------------------------------------------------------
Class A Common Shares 07/28/2000 S 396,274 D $9.63 -0- I (See
(2) below)
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
</TABLE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
* If the Form is filed by more than one Reporting Person, see Instruction
4(b)(v).
(Over)
SEC 1474(3-99)
Page 2 of 4
<PAGE>
FORM 4 (continued)
Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
===============================================================================
<TABLE>
<CAPTION>
10.
9. Owner-
Number ship
of Form
2. Deriv- of
Conver- 5. 7. ative Deriv- 11.
sion Number of Title and Amount Secur- ative Nature
of Derivative 6. of Underlying 8. ities Secur- of
Exer- 4. Securities Date Securities Price Bene- ity: In-
cise 3. Trans- Acquired (A) Exercisable and (Instr. 3 and 4) of ficially Direct direct
Price Trans- action or Disposed Expiration Date ---------------- Deriv- Owned (D) or Bene-
1. of action Code of(D) (Month/Day/Year) Amount ative at End In- ficial
Title of Deriv- Date (Instr. (Instr. 3, ---------------- or Secur- of direct Owner-
Derivative ative (Month/ 8) 4 and 5) Date Expira- Number ity Month (I) ship
Security Secur- Day/ ------ ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr.
(Instr. 3) ity Year) Code V (A) (D) cisable Date Title Shares 5) 4) 4) 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
</TABLE>
Page 3 of 4
Explanation of Responses:
(1) As the parent company of Glaxo Wellcome Inc., the Reporting Person
may be deemed, for purposes of Section 16 of the Securities Exchange
Act of 1934, as amended (the "Act"), to be the beneficial owner of
Class A Common Shares held of record by Glaxo Wellcome Inc. The
Reporting Person may therefore be deemed to be a "10 percent
beneficial owner" for purposes of Section 16 of the Act.
(2) At the time of disposition, these 396,274 shares were held of record
by Glaxo Wellcome Inc., a wholly-owned subsidiary of the Reporting
Person, on behalf of the Reporting Person.
Pursuant to Rule 16a-1(a)(4) promulgated under the Securities Exchange Act
of 1934, as amended, the Reporting Person herein states that this filing
shall not be deemed an admission that he or it is the beneficial owner of
any of the securities covered by this Statement.
** Intentional misstatements or omissions of facts
constitute Federal Criminal Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be
manually signed. If space is insufficient, see
Instruction 6 for procedure.
Potential persons who are to respond to the collection of
information contained in this form are not required to
respond unless the form displays a currently valid OMB
Number.
GLAXO WELLCOME INTERNATIONAL B.V. August 7, 2000
--------------------------------------------- ---------------
By: /s/ Onno Rethmeier Date
-----------------------------------------
Name: Onno Rethmeier
Title: Director
** Signature of Reporting Person
Page 4 of 4
<PAGE>
------------------------------
OMB APPROVAL
[x] Check box if no longer ------------------------------
subject to Section 16. Form 4 or OMB Number 3235-0287
Form 5 obligations may continue. Expires: December 31, 2001
See Instruction 1(b).
------------------------------
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
______________________________________________________________________________
1. Name and Address of Reporting Person*
GLAXO WELLCOME HOLDINGS LIMITED
______________________________________________________________________________
(Last) (First) (Middle)
Greenford, Middlesex, UB6 ONN, England
______________________________________________________________________________
(Street)
______________________________________________________________________________
(City) (State) (Zip)
______________________________________________________________________________
2. Issuer Name and Ticker or Trading Symbol
CliniChem Development Inc. (CCHE)
______________________________________________________________________________
3. IRS Identification Number of Reporting Person, if an Entity (Voluntary)
N/A
______________________________________________________________________________
4. Statement for Month/Year
July 2000
______________________________________________________________________________
5. If Amendment, Date of Original (Month/Year)
N/A
==============================================================================
6. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
[_] Director [x] 10% Owner
[_] Officer (give title below) [_] Other (specify below)
______________________________________________________________________________
7. Individual or Joint/Group Filing (Check applicable line)
[_] Form filed by One Reporting Person
[x] Form filed by more than One Reporting Person
______________________________________________________________________________
Page 1 of 4
<PAGE>
<PAGE>
================================================================================
Table I -- Non-Derivative Securities Acquired, Disposed of,
or Beneficially Owned
================================================================================
<TABLE>
<CAPTION>
6.
4. 5. Owner-
Securities Acquired (A) or Amount of ship
3. Disposed of (D) Securities Form: 7.
Transaction (Instr. 3, 4 and 5) Beneficially Direct Nature of
2. Code -------------------------------
Owned at End (D) or Indirect
1. Transaction (Instr. 8) (A) of Month Indirect Beneficial
Title of Security Date ------------ Amount or Price (Instr. 3 (I) Ownership
(Instr. 3) (month/day/year) Code V (D) and 4) (Instr.4) (Instr. 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
------------------------------------------------------------------------------------------------------------------------------------
Class A Common Shares 07/28/2000 S 396,274 D $9.63 -0- I (See (2)
below)
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
</TABLE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
* If the Form is filed by more than one Reporting Person, see Instruction
4(b)(v).
(Over)
SEC 1474(3-99)
Page 2 of 4
<PAGE>
FORM 4 (continued)
Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
===============================================================================
<TABLE>
<CAPTION>
10.
9. Owner-
Number ship
of Form
2. Deriv- of
Conver- 5. 7. ative Deriv- 11.
sion Number of Title and Amount Secur- ative Nature
of Derivative 6. of Underlying 8. ities Secur- of
Exer- 4. Securities Date Securities Price Bene- ity: In-
cise 3. Trans- Acquired (A) Exercisable and (Instr. 3 and 4) of ficially Direct direct
Price Trans- action or Disposed Expiration Date ---------------- Deriv- Owned (D) or Bene-
1. of action Code of(D) (Month/Day/Year) Amount ative at End In- ficial
Title of Deriv- Date (Instr. (Instr. 3, ---------------- or Secur- of direct Owner-
Derivative ative (Month/ 8) 4 and 5) Date Expira- Number ity Month (I) ship
Security Secur- Day/ ------ ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr.
(Instr. 3) ity Year) Code V (A) (D) cisable Date Title Shares 5) 4) 4) 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
</TABLE>
Page 3 of 4
Explanation of Responses:
(1) As the parent company of Glaxo Wellcome International B.V., which owns
100% of Glaxo Wellcome Inc., the Reporting Person may be deemed, for
purposes of Section 16 of the Securities Exchange Act of 1934, as amended
(the "Act"), to be the beneficial owner of Class A Common Shares held of
record by Glaxo Wellcome Inc. The Reporting Person may therefore be
deemed to be a "10 percent beneficial owner" for purposes of Section 16
of the Act.
(2) At the time of disposition, these 396,274 shares were held of record by
Glaxo Wellcome Inc., a wholly-owned subsidiary of Glaxo Wellcome
International B.V., which in turn is a wholly-owned subsidiary of the
Reporting Person.
Pursuant to Rule 16a-1(a)(4) promulgated under the Securities Exchange Act
of 1934, as amended, the Reporting Person herein states that this filing
shall not be deemed an admission that he or it is the beneficial owner of
any of the securities covered by this Statement.
** Intentional misstatements or omissions of facts
constitute Federal Criminal Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be
manually signed. If space is insufficient, see
Instruction 6 for procedure.
Potential persons who are to respond to the collection of
information contained in this form are not required to
respond unless the form displays a currently valid OMB
Number.
GLAXO WELLCOME HOLDINGS LIMITED August 7, 2000
--------------------------------------------- ---------------
By: /s/ Victoria Llewellyn Date
----------------------------------------
Name: Victoria Llewellyn
Title: Assistant Company Secretary
** Signature of Reporting Person
Page 4 of 4
<PAGE>
<PAGE>
------------------------------
OMB APPROVAL
[x] Check box if no longer ------------------------------
subject to Section 16. Form 4 or OMB Number 3235-0287
Form 5 obligations may continue. Expires: December 31, 2001
See Instruction 1(b).
------------------------------
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
______________________________________________________________________________
1. Name and Address of Reporting Person*
WELLCOME LIMITED
______________________________________________________________________________
(Last) (First) (Middle)
Glaxo Wellcome House, Berkeley Avenue
______________________________________________________________________________
(Street)
Greenford, Middlesex, UB6 ONN, England
______________________________________________________________________________
(City) (State) (Zip)
______________________________________________________________________________
2. Issuer Name and Ticker or Trading Symbol
CliniChem Development Inc. (CCHE)
______________________________________________________________________________
3. IRS Identification Number of Reporting Person, if an Entity (Voluntary)
N/A
______________________________________________________________________________
4. Statement for Month/Year
July 2000
______________________________________________________________________________
5. If Amendment, Date of Original (Month/Year)
N/A
==============================================================================
6. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
[_] Director [x] 10% Owner
[_] Officer (give title below) [_] Other (specify below)
______________________________________________________________________________
7. Individual or Joint/Group Filing (Check applicable line)
[_] Form filed by One Reporting Person
[x] Form filed by more than One Reporting Person
______________________________________________________________________________
Page 1 of 4
<PAGE>
<PAGE>
================================================================================
Table I -- Non-Derivative Securities Acquired, Disposed of,
or Beneficially Owned
================================================================================
<TABLE>
<CAPTION>
6.
4. 5. Owner-
Securities Acquired (A) or Amount of ship
3. Disposed of (D) Securities Form: 7.
Transaction (Instr. 3, 4 and 5) Beneficially Direct Nature of
2. Code ------------------------------- Owned at End (D) or Indirect
1. Transaction (Instr. 8) (A) of Month Indirect Beneficial
Title of Security Date ------------ Amount or Price (Instr. 3 (I) Ownership
(Instr. 3) (month/day/year) Code V (D) and 4) (Instr.4) (Instr. 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
------------------------------------------------------------------------------------------------------------------------------------
Class A Common Shares 07/28/2000 S 396,274 D $9.63 -0- I (See (2)
below)
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
</TABLE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
* If the Form is filed by more than one Reporting Person, see Instruction
4(b)(v).
(Over)
SEC 1474(3-99)
Page 2 of 4
<PAGE>
FORM 4 (continued)
Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
===============================================================================
<TABLE>
<CAPTION>
10.
9. Owner-
Number ship
of Form
2. Deriv- of
Conver- 5. 7. ative Deriv- 11.
sion Number of Title and Amount Secur- ative Nature
of Derivative 6. of Underlying 8. ities Secur- of
Exer- 4. Securities Date Securities Price Bene- ity: In-
cise 3. Trans- Acquired (A) Exercisable and (Instr. 3 and 4) of ficially Direct direct
Price Trans- action or Disposed Expiration Date ---------------- Deriv- Owned (D) or Bene-
1. of action Code of(D) (Month/Day/Year) Amount ative at End In- ficial
Title of Deriv- Date (Instr. (Instr. 3, ---------------- or Secur- of direct Owner-
Derivative ative (Month/ 8) 4 and 5) Date Expira- Number ity Month (I) ship
Security Secur- Day/ ------ ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr.
(Instr. 3) ity Year) Code V (A) (D) cisable Date Title Shares 5) 4) 4) 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
</TABLE>
Page 3 of 4
Explanation of Responses:
(1) As the 83.3% owner of Glaxo Wellcome Holdings Limited, which owns
100% of Glaxo Wellcome International B.V., which in turn owns 100%
of Glaxo Wellcome Inc., the Reporting Person may be deemed, for
purposes of Section 16 of the Securities Exchange Act of 1934, as
amended (the "Act"), to be the beneficial owner of Class A Common
Shares held of record by Glaxo Wellcome Inc. Accordingly, the
Reporting Person may be deemed to be a "10 percent beneficial
owner" for purposes of Section 16 of the Act.
(2) At the time of disposition, these 396,274 shares were held of
record by Glaxo Wellcome Inc., which is a wholly-owned subsidiary
of Glaxo Wellcome International B.V., which in turn is a wholly-
owned subsidiary of Glaxo Wellcome Holdings Limited, which is
83.3% owned by the Reporting Person.
Pursuant to Rule 16a-1(a)(4) promulgated under the Securities Exchange Act
of 1934, as amended, the Reporting Person herein states that this filing
shall not be deemed an admission that he or it is the beneficial owner of
any of the securities covered by this Statement.
** Intentional misstatements or omissions of facts
constitute Federal Criminal Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be
manually signed. If space is insufficient, see
Instruction 6 for procedure.
Potential persons who are to respond to the collection of
information contained in this form are not required to
respond unless the form displays a currently valid OMB
Number.
GLAXO WELLCOME INC. August 7, 2000
--------------------------------------------- ---------------
By: /s/ S.M. Bicknell Date
--------------------------------------
Name: S.M. Bicknell
Title: Assistant Secretary
** Signature of Reporting Person
Page 4 of 4
<PAGE>
<PAGE>
------------------------------
OMB APPROVAL
[x] Check box if no longer ------------------------------
subject to Section 16. Form 4 or OMB Number 3235-0287
Form 5 obligations may continue. Expires: December 31, 2001
See Instruction 1(b).
------------------------------
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
______________________________________________________________________________
1. Name and Address of Reporting Person*
GLAXO WELLCOME PLC
______________________________________________________________________________
(Last) (First) (Middle)
Glaxo Wellcome House, Berkeley Avenue
______________________________________________________________________________
(Street)
Greenford, Middlesex, UB6 ONN, England
______________________________________________________________________________
(City) (State) (Zip)
______________________________________________________________________________
2. Issuer Name and Ticker or Trading Symbol
CliniChem Development Inc. (CCHE)
______________________________________________________________________________
3. IRS Identification Number of Reporting Person, if an Entity (Voluntary)
N/A
______________________________________________________________________________
4. Statement for Month/Year
July 2000
______________________________________________________________________________
5. If Amendment, Date of Original (Month/Year)
N/A
==============================================================================
6. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
[_] Director [x] 10% Owner
[_] Officer (give title below) [_] Other (specify below)
______________________________________________________________________________
7. Individual or Joint/Group Filing (Check applicable line)
[_] Form filed by One Reporting Person
[x] Form filed by more than One Reporting Person
______________________________________________________________________________
Page 1 of 4
<PAGE>
<PAGE>
================================================================================
Table I -- Non-Derivative Securities Acquired, Disposed of,
or Beneficially Owned
================================================================================
<TABLE>
<CAPTION>
6.
4. 5. Owner-
Securities Acquired (A) or Amount of ship
3. Disposed of (D) Securities Form: 7.
Transaction (Instr. 3, 4 and 5) Beneficially Direct Nature of
2. Code ------------------------------- Owned at End (D) or Indirect
1. Transaction (Instr. 8) (A) of Month Indirect Beneficial
Title of Security Date ------------ Amount or Price (Instr. 3 (I) Ownership
(Instr. 3) (month/day/year) Code V (D) and 4) (Instr.4) (Instr. 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
------------------------------------------------------------------------------------------------------------------------------------
Class A Common Shares 07/28/2000 S 396,274 D $9.63 -0- I (See (2)
below)
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
</TABLE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
* If the Form is filed by more than one Reporting Person, see Instruction
4(b)(v).
(Over)
SEC 1474(3-99)
Page 2 of 4
<PAGE>
FORM 4 (continued)
Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
===============================================================================
<TABLE>
<CAPTION>
10.
9. Owner-
Number ship
of Form
2. Deriv- of
Conver- 5. 7. ative Deriv- 11.
sion Number of Title and Amount Secur- ative Nature
of Derivative 6. of Underlying 8. ities Secur- of
Exer- 4. Securities Date Securities Price Bene- ity: In-
cise 3. Trans- Acquired (A) Exercisable and (Instr. 3 and 4) of ficially Direct direct
Price Trans- action or Disposed Expiration Date ---------------- Deriv- Owned (D) or Bene-
1. of action Code of(D) (Month/Day/Year) Amount ative at End In- ficial
Title of Deriv- Date (Instr. (Instr. 3, ---------------- or Secur- of direct Owner-
Derivative ative (Month/ 8) 4 and 5) Date Expira- Number ity Month (I) ship
Security Secur- Day/ ------ ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr.
(Instr. 3) ity Year) Code V (A) (D) cisable Date Title Shares 5) 4) 4) 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
</TABLE>
Page 3 of 4
Explanation of Responses:
(1) As the parent company of Wellcome Limited, which owns 83.3% of Glaxo
Wellcome Holdings Limited, which in turn owns 100% of Glaxo Wellcome
International B.V., which owns 100% of Glaxo Wellcome Inc., the
Reporting Person may be deemed, for purposes of Section 16 of the
Securities Exchange Act of 1934, as amended (the "Act"), to be the
beneficial owner of Class A Common Shares held of record by Glaxo
Wellcome Inc. and, therefore, may be deemed to be a "10 percent
beneficial owner" for purposes of Section 16 of the Act.
(2) At the time of disposition, these 396,274 shares were held of record
by Glaxo Wellcome Inc., which is a wholly-owned subsidiary of Glaxo
Wellcome International B.V., which in turn is a wholly-owned subsidiary
of Glaxo Wellcome Holdings Limited, which is 83.3% owned by Wellcome
Limited, which is a wholly-owned subsidiary of the Reporting Person.
Pursuant to Rule 16a-1(a)(4) promulgated under the Securities Exchange Act
of 1934, as amended, the Reporting Person herein states that this filing
shall not be deemed an admission that he or it is the beneficial owner of
any of the securities covered by this Statement.
** Intentional misstatements or omissions of facts
constitute Federal Criminal Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be
manually signed. If space is insufficient, see
Instruction 6 for procedure.
Potential persons who are to respond to the collection of
information contained in this form are not required to
respond unless the form displays a currently valid OMB
Number.
GLAXO WELLCOME PLC August 7, 2000
--------------------------------------------- ---------------
By: /s/ S.M. Bicknell Date
--------------------------------------
Name: S.M. Bicknell
Title: Assistant Corporate Secretary
** Signature of Reporting Person
Page 4 of 4
